OTIPRIO® ciprofloxacin otic suspension 6%

OTIVIDEX™

A sustained-exposure formulation of the steroid dexamethasone in development for patients with Ménière’s disease
LEARN MORE »

OTO-313

A sustained exposure formulation of the NMDA receptor antagonist gacyclidine in development for patients with tinnitus
LEARN MORE »

Hearing Loss Programs

Otonomy is developing three programs for the prevention and treatment of sensorineural hearing loss
LEARN MORE »